We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
Dedicated to our clients' success
Services
Intellectual Property
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Meet our team
Our knowledge, expertise & publications
View all
Events
Deals & Cases
Careers
14 December 2018
Resistell has closed an oversubscribed seed financing round. Lead Investors Michal Bartos and Occident Group AG, together with Hemex AG and five other private investors invested in the EPFL spin-off developing the world’s fastest phenotypic antibiotic susceptibility test identifying drug resistance within hours instead of days. Resistell AG was incorporated in April 2018 in Basel to take the technology to the next level and to transfer the laboratory prototypes into a Minimal Viable Product that could be easily operated by laboratory technicians in hospital laboratories.
VISCHER AG advised Resistell, the team was led by Matthias Staehelin (Partner) with Luzius Zumstein (Associate) both Corporate.
Categories: Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk, Deals & Cases
Attorney at Law and Civil Law Notary (BS/BL)
Attorney at Law
Swiss dental startup Odne (former Lumendo) has raised USD 5.5m to fund the upcoming US market launch...
Artiria Medical SA, a Swiss neurovascular MedTech company developing next-generation...
GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional...